Jump to start of content

Complete requirements by 12/31/18 to avoid a change in certification status Expand/Collapse the ABIM alert.

Sign in to your Physician Portal to view any remaining requirements for the year. Not completing these requirements by 12/31/18 could result in a change to your certification status.

Breadcrumb trail:

Cardiovascular Board Cardiovascular Disease Exam Committee

Expand All | Collapse All

Mario J. Garcia, MD, Chair

Dr. Garcia is board certified in Internal Medicine, Cardiovascular Disease and Echocardiography. He is Chief of Cardiology at Montefiore Medical Center, and co-Director of the Montefiore Einstein Center for Heart and Vascular Care. He is also Professor of Medicine and Radiology, Albert Einstein College of Medicine.

Dr. Garcia’s previous positions include Director of Cardiac Imaging and Professor of Medicine and Radiology at Mount Sinai Hospital and Medical School; Director of Cardiac Imaging, Cleveland Clinic; and Assistant Professor of Medicine at Dartmouth Hitchcock and the White River Junction VA Medical Center.

He is presently Chair of the American Board of Internal Medicine Cardiovascular Board Cardiovascular Disease Exam Committee, National Board of Echocardiography, Montefiore Accountable Care Organization, American Heart Association – Founder Affiliate, Centro de Diagnóstico y Medicina Avanzada, and Conferencias Médicas y Telemedicina (Santo Domingo, Dominican Republic). He is a past member of the Board of the American Society of Echocardiography, American Society of Nuclear Cardiology, Society of Cardiovascular Computed Tomography and the Intersocietal Accreditation Council.

Dr. Garcia received his medical degree from the Universidad Nacional Pedro Henríquez Ureña, Dominican Republic. He completed training in internal medicine and cardiology at St. Vincent’s Medical Center in Bridgeport, Connecticut; nuclear cardiology at Massachusetts General Hospital; and echocardiography at Cleveland Clinic.

As of April 2018, Dr. Garcia reported the following external relationships.

Work as an author or editor for the following companies, with compensation as listed:

  • Elsevier, receiving royalties for textbook authorship.
  • Wolters Kluwer Health, receiving royalties for textbook authorship.

Dr. Garcia serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • National Board of Medical Examiners, National Board of Echocardiography Exam Committee, receiving reimbursement for travel expenses.

Christopher P. Appleton, MD

Dr. Appleton, board certified in Internal Medicine and Cardiovascular Disease, is Professor of privileges in Clinical Research at the Mayo School of Graduate Medical Education, Scottsdale.

His clinical and research interests include left ventricular diastolic function and diastolic heart failure; pericardial diseases; physiology and treatment of hypertrophic cardiomyopathy, both obstructive and non-obstructive; restrictive cardiomyopathy; and left atrial function, in normal and disease states. Dr. Appleton began an active career in these topics in 1984, publishing both experimental and clinical research using cardiac ultrasound in new ways as a diagnostic tool. The majority of current research is now clinical. Dr. Appleton is considered a national/world expert on all four topics. He is a member of the American Board of Internal Medicine Cardiovascular Board Cardiovascular Disease Exam Committee.

Dr. Appleton received his medical degree from the University of Washington School of Medicine. He completed his internship, residency training and chief residency at the University of Arizona Health Sciences Center. He completed a fellowship in cardiac research at the Tucson Veterans Administration Hospital and a cardiovascular fellowship at Stanford University. He has been at the Mayo Clinic Arizona since 1993 and was Cardiovascular Division Chair from 1995 through 2004.

As of January 2017, Dr. Appleton reported no external relationships.

Dimitri C. Cassimatis, MD

Dr. Cassimatis is Director of the Coronary Care Unit at Emory University Hospital Midtown in Atlanta, Georgia, and divides his clinical time between Emory Midtown and Grady Memorial Hospital. He co-directs the first-year medical student cardiovascular pathophysiology module at Emory's School of Medicine, and is a small group faculty advisor there as well. Dr. Cassimatis is board certified in Internal Medicine, Cardiovascular Disease and Adult Transthoracic Echocardiography.

Before joining Emory as an Assistant Professor in 2010, Dr. Cassimatis spent 11 years as a physician in the United States Army. He served as Chief of the Cardiology Service at the U.S. Army's Landstuhl Regional Medical Center, and prior to this was Chief of the Cardiology Clinic there. He has served on both Ethics and Peer Review Committees on the clinical side, and Admissions and Curriculum Committees on the educational side.

Dr. Cassimatis is a member of the American Board of Internal Medicine Cardiovascular Board Cardiovascular Disease Exam Committee. He serves on the Board of Directors of the Medical Association of Atlanta. He has received numerous awards, including two teaching awards from the Emory Cardiology fellows, two Meritorious Service Medals from the U.S. Army, and the Graves B. Erskine Award for top graduating fellow at Walter Reed in 2005.

Dr. Cassimatis received his bachelor's degree in biochemistry at the University of Chicago and his medical degree from Harvard University, where he was selected to give one of the commencement addresses at his graduation. He completed his internal medicine and cardiology training at Walter Reed Army Medical Center in Washington, DC.

As of July 2017, Dr. Cassimatis reported no external relationships.

Dr. Cassimatis serves in significant roles with the following organization, receiving reimbursement or compensation as listed:

  • Medical Association of Atlanta, member of Board of Trustees, receiving reimbursement for travel expenses.

Dr. Cassimatis also teaches a cardiology pathophysiology course for Emory University medical students, and also teaches cardiology fellows in clinical practice.

Mina K. Chung, MD

Dr. Chung is board certified in Internal Medicine, Cardiovascular Disease, and Clinical Cardiac Electrophysiology. She is a staff Clinical Cardiac Electrophysiologist in the Heart and Vascular Institute Department of Cardiovascular Medicine and in the Lerner Research Institute Department of Molecular Cardiology at the Cleveland Clinic. She is a Professor of Medicine in the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.

Dr. Chung is a member of the American Board of Internal Medicine Cardiovascular Board Cardiovascular Disease Exam Committee. She is also active on committees within the American Heart Association (AHA), American College of Cardiology (ACC) and the Heart Rhythm Society (HRS). She has been Chair of the HRS Scientific and Clinical Documents Committee and is a member of the AHA Electrocardiology and Arrhythmias Committee of the Clinical Cardiology Council, the ACC EP Section Leadership Council, and the Cleveland Clinic Institutional Review Board. She has served on several consensus document and guideline writing committees and the National Institutes of Health (NIH) Clinical Trial Review Committee.

Dr. Chung has authored or co-authored numerous peer-reviewed publications. Her research interests include translational genomics of atrial fibrillation, clinical arrhythmia outcomes and electrophysiology device and ablation outcomes. She is a principal investigator for an NIH-funded grant on functional genomics of atrial fibrillation.

Dr. Chung received a bachelor's degree in chemistry from the University of California, San Diego, and her medical degree from Washington University School of Medicine in St. Louis, Missouri, where she also completed internal medicine residency and chief residency and cardiology and cardiac electrophysiology fellowships.

As of April 2017, Dr. Chung reported the following external relationships:

Funding for clinical trial expenses and staff, paid to the Cleveland Clinic, from the following company:

  • ZOLL, for a trial of a wearable cardioverter defibrillator post-heart attack.

Service on data and safety monitoring boards for the following company, with compensation for travel expenses:

  • Amarin, for a trial of an omega-3 fatty acid.

Work funded by educational grants from industry from the following companies:

  • Biotronik, for serving as a member of the steering committee for an international mentoring effort and education for women in cardiac electrophysiology, receiving reimbursement for travel expenses.
  • Medtronic, for Women in Electrophysiology, receiving reimbursement for travel expenses.

Work as an author or editor for following companies, with compensation as listed:

  • UpToDate, receiving compensation for authorship.
  • American Heart Association, receiving compensation as Associate Editor for Circulation: Arrhythmia and Electrophysiology.

Dr. Chung serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • American College of Cardiology, Member of the Electrophysiology Section Leadership Council, without compensation.
  • American Heart Association, Vice Chair, Arrhythmia and ECG Committee, without compensation.
  • Heart Rhythm Society, Chair of Scientific and Clinical Documents Committee, without compensation.

Larry S. Dean, MD

Dr. Dean is currently a Professor of Medicine and Surgery at the University of Washington (UW) School of Medicine and Director of the UW Medicine Regional Heart Center in Seattle, Washington. He is board certified in Internal Medicine, Cardiovascular Disease and Interventional Cardiology. Dr. Dean specializes in interventional cardiology and is widely published in that field.

Previously, Dr. Dean was a Professor of Medicine at the University of Alabama (UAB) School of Medicine where he also served as an Assistant Medical Director of UAB Hospital. While there, he practiced general and interventional cardiology and was involved in the early development of intracoronary stents.

Dr. Dean is a member of the American Board of Internal Medicine Cardiovascular Board Cardiovascular Disease Committee. He is a fellow of the American College of Cardiology, the American Heart Association and is a Master Interventionalist of the Society for Cardiovascular Angiography and Interventions (SCAI). He is also a past President of SCAI. In addition, he is a member of the American Association for Physician Leadership and the American Medical Informatics Association.

He received his undergraduate degree and his medical degree from the University of Alabama. Following medical school, Dr. Dean served his internship and residency at the University of Washington School of Medicine and received cardiology training, including interventional cardiology, at the University of Alabama School of Medicine. He also holds a certificate in Medical Management from the University of Washington.

As of January 2017, Dr. Dean reported the following external relationships:

Funding for clinical trial expenses and staff, paid to the University of Washington School of Medicine, from the following company:

  • Edwards LifeSciences, for trials evaluating the SAPIEN heart valve (PARTNER trials).

Attendance at investigators' meetings, with compensation as listed from the following company:

  • Edwards LifeSciences, held in conjunction with major professional meetings where study issues were discussed with investigators involved with trials evaluating the SAPIEN heart valve (PARTNER trials); receiving reimbursement for travel expenses.

Dr. Dean serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • American College of Cardiology, serves on the Transcatheter Valve Therapy Registry Stakeholders Committee, receiving reimbursement for per diem and travel expenses.
  • Society for Cardiovascular Angiography and Interventions, Member, Budget and Finance Committee, receiving no compensation.

William Lane Duvall, MD

Dr. Duvall is the Director of Nuclear Cardiology at Hartford Hospital in Hartford, Connecticut, and Associate Professor of Medicine at the University of Connecticut School of Medicine. He is board certified in Internal Medicine, Cardiovascular Disease, Nuclear Cardiology and Adult Echocardiography.

Previously, Dr. Duvall worked as a non-invasive cardiologist at Mount Sinai Medical Center for almost 10 years, most recently serving as an Associate Professor of Medicine. During his time there, he worked full-time in the echocardiography and nuclear cardiology laboratories and served in several administrative positions including in the fellowship program and the cardiac care unit.

Dr. Duvall is a member of the American Board of Internal Medicine Cardiovascular Board Cardiovascular Disease Exam Committee. He is actively involved with the American Society of Nuclear Cardiology, currently serving on the Board of Directors. Additionally, he is a member of the Registry Oversight Committee and the Deputy Chair of the Health Policy Committee.

Dr. Duvall received a bachelor’s degree in molecular biology from Princeton University and his medical degree from Yale University. He completed his internal medicine internship and residency at Duke University Medical Center, and his cardiovascular disease fellowship at Mount Sinai Medical Center in New York City.

As of July 2017, Dr. Duvall reported the following external relationships:

Dr. Duvall serves in significant roles with the following organization, receiving reimbursement or compensation as listed:

  • American Society of Nuclear Cardiology, Board of Directors, Health Care Policy Committee, ImageGuide Registry Committee, Nuclear Cardiology Today Speaker, receiving honoraria and reimbursement for travel expenses.

Marie D. Gerhard-Herman, MD

Dr. Gerhard-Herman is a cardiovascular medicine specialist at Brigham and Women’s Hospital (BWH). In addition, she is an associate professor of medicine at Harvard Medical School.

Dr. Gerhard-Herman’s clinical interests include deep vein thrombosis, general vascular medicine and Hutchinson-Gilford Progeria syndrome. She has authored over 75 peer-reviewed journal articles, as well as numerous educational materials, clinical guidelines and reports. Her research has received support from the National Institutes of Health and Progeria Research Foundation. She is a member of the American Board of Internal Medicine Cardiovascular Board Cardiovascular Disease Exam Committee.

She received her medical degree from Northeastern Ohio University Medical University. Dr. Gerhard-Herman completed a residency program in internal medicine at Boston City Hospital/Thorndike Memorial Lab (now Boston Medical Center), as well as fellowship programs in cardiovascular disease and vascular medicine at BWH. She is board certified in cardiovascular disease.

As of January 2017, Dr. Gerhard-Herman reported the following external relationships:

Dr. Gerhard-Herman serves in significant roles with the following organization(s), receiving reimbursement or compensation as listed:

  • American College of Cardiology, Chair, Peripheral Arterial Disease (PAD) Guideline Writing Committee; receiving reimbursement for travel expenses.
  • Progeria Research Foundation, grant funding provided to Brigham and Women's Hospital for vascular ultrasound imaging to assess phenotype and response to therapy in children with Hutchinson-Gilford (HG) progeria syndrome; receiving salary support.

Garrie J. Haas, MD

Dr. Haas is Professor of Clinical Medicine at The Ohio State University Wexner Medical Center in Columbus, Ohio. He is the Section Chief of the Advanced Heart Failure and Cardiac Transplant Program at Ohio State, and is the Medical Director of Heart Failure for the Wexner Medical Center. Dr. Haas is board certified in Internal Medicine, Cardiovascular Disease, and Advanced Heart Failure & Transplant Cardiology.

He was formerly the Director of the Heart Failure Intensive Care Unit at Cleveland Clinic, and directed the heart failure disease management program at Riverside Methodist Hospital in Columbus.

Dr. Haas is a member of the American Board of Internal Medicine Cardiology Board Cardiovascular Disease Exam Committee. Previously, he held the directorship of the Heart and Vascular Research Organization (HVRO) at Ohio State, which manages over 150 clinical trials for the divisions of cardiology, cardiovascular surgery, and vascular medicine. He is personally actively involved as principle investigator for multiple heart failure clinical trials. Dr. Haas is a member of the heart failure subcommittee of the American College of Cardiology-affiliated Society of Cardiovascular Patient Care. He was previously the Chair of the Heart Failure version 3 writing committee for ACC.

Dr. Haas received his degree in zoology from Ohio Wesleyan University, and earned his medical degree from Marshall University in Huntington, West Virginia. He completed his medicine residency at The Ohio State University College of Medicine. Dr. Haas also completed fellowships in cardiology, interventional cardiology and heart failure/cardiac transplantation at Ohio State’s College of Medicine.

As of July 2018, Dr. Haas reported the following external relationships:

Funding for clinical trial expenses and staff, paid to The Ohio State University, from the following companies:

  • Bristol-Myers Squibb, for a clinical trial investigating an intravenous drug for decompensated heart failure.

Service on data and safety monitoring boards for the following companies, with honoraria:

  • Medtronic, for participating on the adjudication committee for a trial utilizing integrated device diagnostics to identify and treat heart failure.

Jonathan L. Halperin, MD

Dr. Halperin, a board certified internist and cardiologist, is the Robert and Harriet Heilbrunn Professor of Medicine (Cardiology) at the Icahn School of Medicine at Mount Sinai. He joined the Mount Sinai faculty in 1980 and played a key role in the formation of the Cardiovascular Institute, a leading center for integrated cardiovascular research, education and patient care. Today he is Associate Director of the Institute.

As the principal cardiologist responsible for the design and execution of the Stroke Prevention in Atrial Fibrillation (SPAF) clinical trials, he helped develop antithrombotic strategies to prevent stroke among the millions of people with atrial fibrillation. He was co-Chairman of the Executive Steering Committee of the SPORTIF trials, which evaluated the first oral direct thrombin inhibitor, and served on the Executive Steering Committee of the ROCKET-AF trial, which evaluated the first oral factor Xa inhibitor for this indication. He is currently engaged in studies developing therapeutic approaches to an array of cardiovascular disease states, including atrial fibrillation.

Dr. Halperin is a member of the American Board of Internal Medicine Cardiovascular Board Cardiovascular Disease Exam Committee. He was the recipient of the Heart of New York Award for Achievement in Cardiovascular Science and Medicine and the Jacobi Medallion in recognition of distinguished achievement in the field of medicine at the Mount Sinai Medical Center, as well as several teaching awards. He serves on consensus and writing panels that issue clinical practice guidelines for management of patients with various cardiovascular disorders, is Chair of the ACC/AHA Task Force on Practice Guidelines, co-Chair of the ACC Clinical Competence Committee, and Deputy Editor of the Journal of the American College of Cardiology. He is also past President of the Society for Vascular Medicine and the New York City affiliate of the American Heart Association.

Dr. Halperin was educated at Columbia University and the Boston University School of Medicine.

As of January 2017, Dr. Halperin reported the following external relationships:

Attendance at investigators' meetings, with compensation for travel expenses and honoraria from the following company:

  • Pfizer, for the EMANATE trial, investigating the use of the oral factor Xa inhibitor, apixaban, in patients with atrial fibrillation undergoing cardioversion; receives reimbursement for travel expenses and honoraria.

Service on a research-related expert panel or advisory board for the following companies, with compensation as listed:

  • Boehringer Ingelheim, Chair, Global Advisory Committee on dabigatran; receives reimbursement for travel expenses and consulting fees.

Consulting on design of new drugs or devices, clinical trials, the use of specific agents or other research-related activities for the following companies, with compensation as listed:

  • Bayer, Member of the Executive Steering Committee of the MARINER trial of rivaroxaban for prevention of venous thromboembolism in medically ill patients, receiving consulting fees.
  • Janssen Pharmaceutica, Member of the Executive Steering Committee of the PIONEER AF/PCI trial investigating the use of the oral factor Xa inhibitor, rivaroxaban, in patients with atrial fibrillation undergoing percutaneous coronary intervention, receiving consulting fees.
  • Medtronic Inc., Member of the Executive Steering Committee for the REVEAL-AF study of an implanted cardiac rhythm monitor in patients at risk of developing atrial fibrillation, receiving consulting fees.
  • Pfizer, Member of the Executive Steering Committee of the EMANATE trial investigating the use of the oral factor Xa inhibitor, apixaban, in patients with recently diagnosed atrial fibrillation undergoing cardioversion, receiving consulting fees.

Post-marketing clinical research, from the following company:

  • Boehringer Ingelheim, Member of the Executive Steering Committee of the GLORIA-AF Registry, which is evaluating the selection and initiation of anticoagulant therapy for stroke prevention in patients with non-valvular atrial fibrillation; receiving consulting fees.

Work as an author or editor for the following companies, with compensation as listed:

  • American College of Cardiology Foundation, Deputy Editor of the Journal of American College of Cardiology, receiving reimbursement for travel.

Dr. Halperin serves in significant roles with the following organization(s), with compensation as listed:

  • HWL, LLC, a software company enabling physicians to access clinical data presented through a highly usable design interface, receiving compensation.

Dr. Halperin serves in significant roles with the following organization(s), receiving reimbursement or compensation as listed:

  • American College of Cardiology, co-Chair, Competency Management Committee, receiving reimbursement for travel expenses.
  • American College of Cardiology and American Heart Association, Chair, ACC/AHA Task Force on Practice Guidelines, receiving reimbursement for travel expenses.

Dr. Halperin also serves on the Antithrombotic Trials Leadership and Steering (ATLAS) Group, an academic research organization developing cardiovascular clinical trials in the field of antithrombotic therapy, receiving consulting fees.

Barbara Hutchinson, MD, PhD

Dr. Hutchinson is the Managing Partner of Chesapeake Cardiac Care, P.A., a cardiology practice located in Annapolis, Maryland. She is board certified in Internal Medicine, Cardiovascular Disease and Sleep Medicine. Dr. Hutchinson is also an instructor in the Department of Internal Medicine at University of Maryland Medical Center in Baltimore, Maryland.

Previously, Dr. Hutchinson was Medical Director of the Heart and Vascular Unit at Anne Arundel Medical Center and Intensivist at Mercy Medical Center. She was the first African American to hold the title of Chief Resident in Internal Medicine at University of Maryland Hospital. She was also a lecturer in Pharmacology at University of District of Columbia, in the Department of Respiratory Therapy.

Dr. Hutchinson is a member of the American Board of Internal Medicine Cardiovascular Board Cardiovascular Disease Exam Committee. She is President of the Association of Black Cardiologists, and a Fellow of the American College of Cardiology (FACC). Patients from all over the world seek her out. She is a noted speaker on heart disease in women and how sleep affects heart health. Additionally, Dr. Hutchinson is the recipient of numerous awards for her work.

Dr. Hutchinson was born in Trinidad and Tobago and she earned her bachelor of science degree in chemistry at the University of the West Indies. She earned her doctoral degree in cardiovascular pharmacology from Howard University in Washington, District of Columbia, and her medical degree and subsequent fellowship in cardiology from the University of Maryland in Baltimore, Maryland.

As of January 2017, Dr. Hutchinson reported the following external relationships:

Dr. Hutchinson serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • Association of Black Cardiologists, serving as President, without compensation.

Geoffrey A. Rose, MD

Dr. Rose is Chief, Division of Adult Cardiology for the Sanger Heart & Vascular Institute (SHVI) at Atrium Health, one of the largest not-for-profit health care systems in the US. He formerly served as SHVI’s Medical Director of Cardiac Imaging. His clinical work centers on providing advanced imaging support for SHVI’s Structural Heart and Intraoperative Echocardiography Programs. He is board certified in Cardiovascular Disease (ABIM) and certified in Adult Comprehensive Echocardiography (National Board of Echocardiography). Dr. Rose is Professor of Medicine at Atrium Health and Clinical Professor of Medicine at the University of North Carolina at Chapel Hill School of Medicine.

Dr. Rose has served as President of the Intersocietal Accreditation Commission (IAC): Echocardiography and as Chair of the IAC Board of Directors. He represents the American Society of Echocardiography (ASE) at the AMA’s Relative Value Scale Update Committee. Dr. Rose was the Program Chair for the ASE 28th Annual Scientific Sessions, and he joined the ASE Board of Directors in 2017.

Dr. Rose is a member of the American Board of Internal Medicine Cardiovascular Board Cardiovascular Disease Exam Committee. Additionally, he serves as a member of the Board of Advisors for the Carolina Physicians Alliance, a clinically integrated network developed jointly by Atrium Health and physicians based in the Charlotte, North Carolina region.

Dr. Rose’s educational background and training include a medical degree from the University of Pennsylvania School of Medicine; internship and residency at the Hospital of the University of Pennsylvania (Chief Resident); and fellowship in cardiology at the Massachusetts General Hospital, where he completed a subspecialty fellowship in cardiac ultrasound.

As of July 2017, Dr. Ryan reported the following external relationships:

Dr. Rose serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • American Society of Echocardiography, Board Member, receiving reimbursement for travel expenses.

Dr. Rose also reports that his institution participates in a “think tank” with other cardiovascular groups, receiving industry support for reimbursement for travel expenses.

Chittur A. Sivaram, MD

Dr. Sivaram is a practicing cardiologist at OU Heart Lung and Vascular Center, OH Health Science Center and is affiliated with Edmond Medical Center in Oklahoma City, Oklahoma. He is a member of the ABIM Cardiovascular Board Cardiovascular Disease Exam Committee.

Dr. Sivaram graduated from Government Medical College Kozhikode.

As of January 2017, Dr. Sivaram reported the following external relationships:

Service on data and safety monitoring boards for the following companies, with compensation for travel expenses and/or honoraria, paid to the University of Oklahoma:

  • Medtronic Inc., for a trial of a bioprosthetic valve in aortic position, receiving honoraria.
  • NaviGate Cardiac Structures, Inc., for a trial of newer valve devices, receiving honoraria and reimbursement for travel expenses.

Dr. Sivaram serves in significant roles with the following organization, receiving reimbursement or compensation as listed:

  • American College of Cardiology, Member of the Competency Management Committee, Member of the Life Long Learning Oversight Committee, without compensation.